Alphageneron Pharmaceuticals, Inc., is a privately-held clinical stage biotechnology company, developing targeted natural killer (NK) cell therapies which are supported by Companion Diagnostics. Alphageneron’s team is comprised of industry veterans
AP-205™ is being developed as an ‘off-the-shelf’ CAR-engineered NK cell therapy which targets tumors expressing membrane Hsp70. Gene editing will improve persistence, potency and efficacy.
AP-161™ is an allogeneic targeted NK cell therapy that targets tumors expressing mHsp70. For this, cryopreserved NK cells expanded from peripheral blood mononuclear cells (PBMCs) obtained from healthy donors are thawed
ENKASTIM™ is a targeted autologous NK cell therapy that activates the patient’s own NK cells to target cancers expressing membrane Hsp70 (“mHsp70”), a cancer-specific biomarker which is highly expressed on
Unique, Novel Tumor-Specific Biomarker Our lead clinical stage natural killer (NK) cell therapy, is an autologous platform technology that activates NK cells to kill cancers expressing a unique membrane form
Gabriele Multhoff, PhD Dr. Gabriele Multhoff is Professor of Experimental Radiation Oncology and Radiobiology in the Department of Radiation Oncology at the Technische Universität München (TUM) and Head of the